Clinical Research

CNO is involved in clinical research within a wide array of neurological diseases. We believe in contributing to the development of new therapies and adding to the collective understanding of neurosciences and medicine.

Help Us Make Wheelchairs Obsolete

Why clinical research?

At CNO, research and clinical practice go hand in hand.

We continuously participate in a number of clinical trials aiming to create better treatments for a variety of diseases: Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.

Cutting-edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and to help advance the treatments themselves. When it comes to neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of doctors, nurses and patients.

Research complements our therapeutic approach.

Francois Jacques, Neurologist, Founder.

Multiple Sclerosis

In the past few decades the MS field has witnessed a rapid expansion of new therapies. CNO has been involved for the past 25 years in the development of most of the new therapies for MS. CNO continues to contribute to the field and remains at the forefront of MS clinical research.

Myasthenia Gravis

The past decade has seen transformative developments in the treatment landscape of Myasthenia Gravis. New treatments with innovative mechanisms including B cell depletion, complement inhibitions, and neonatal FC receptor blockade are now available and offer the prospect of long-term disease remission.

Parkinson's Disease

Parkinson’s Disease research has achieved tremendous strides in the past decades. Research has ranged from better understanding of the underlying disease mechanisms and how to improve symptomatic treatments to interventions that slow down or halt the disease progression.

Multifocal Motor Neuropathy

Multifocal Motor Neuropathy (MMN) is a rare autoimmune disease affecting peripheral motor nerves. It is manifested by slowly progressive painless asymmetrical weakness of hand and/or legs without any sensory loss.

Amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease affecting both the central and peripheral nervous systems, with an estimated incidence of 1 to 3 cases per 100,000 people per year.

Alzheimer’s Disease

Alzheimer’s Disease is a progressive and eventually fatal brain disease, responsible for 60-80% of all dementia cases. The disease processes begin decades before the onset of symptoms, making early detection and intervention a priority.

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) (CIDP) is an autoimmune disease affecting the peripheral nervous system.

Glioblastoma Multiforme

Glioblastoma Multiforme is the most aggressive and common form of primary malignant brain tumor.